Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Kinehara, Yuhei; Minami, Toshiyuki; Kijima, Takashi; Hoshino, Shigenori; Morimura, Osamu; Otsuka, Tomoyuki; Hayama, Yoshitomo; Fukushima, Kiyoharu; Takeuchi, Yoshiko; Higashiguchi, Masayoshi; Miyake, Kotaro; Hirata, Haruhiko; Nagatomo, Izumi; Inoue, Koji; Takeda, Yoshito; Kida, Hiroshi; Kumanogoh, Atsushi
• Is Part Of: Lung cancer. Volume 87:Issue 3(2015:Mar.)
• Page Start: 321
• Page End: 325
• Publication Date: 2015-03
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.01.003
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Standard therapeutic strategies for relapsed-SCLC remain unestablished.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">HER2 is reported to be a negative prognostic factor of extensive disease-SCLC.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">This case report first shows the potential of trastuzumab-based therapy in SCLC.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Antitumor effects of trastuzumab are presumed to be caused mainly by ADCC.</p> </list-item> </list> </p> </sec> </abstract>